Bruce Eaton, PhD

Chairman and Chief Executive Officer

Dr. Eaton serves as Chairman and Chief Executive Officer of i2 Pharmaceuticals.  He has been active in commercial Bioscience endeavors in Colorado and California and held several executive-level leadership positions.   With 35 years in both therapeutics and human diagnostics he is passionate about human health and wellness.  His biotech experience also includes participation in successful transitions of private companies becoming public. Dr. Eaton has to date founded five companies in the U.S. focused on pharmaceuticals or diagnostics. Dr. Eaton has notable experience in M&A and post-acquisition integration.  He has been involved in the development of FDA approved diagnostic and therapeutic products, as well as, establishing profitable service businesses for the translational medicine life sciences market. Early in his biotech career he served as Vice President of Chemistry at NeXstar Pharmaceuticals where he directed the efforts of more than 50 scientists including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen™ (Eyetech Pharmaceuticals), marketed by Pfizer for age-related macular degeneration.  Leading this chemistry effort, he was responsible for the acquisition and operation of chemistry companies in both the US and Europe. Dr. Bruce Eaton is an accomplished innovator with more than 80 patents issued worldwide. Dr. Eaton received his Ph.D. degree in Chemistry from the University of California at Berkeley.  In addition to his role as Chairman and CEO of i2 Pharmaceuticals, he currently serves on the board of directors of Velocity Sciences, Galaxy Ophthalmics, Lumos Technology, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) and the Colorado Bioscience Association (CBSA).

Back to Leadership Team